Atroveran

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atroveran

Property Description
Active ingredient Papaverine (often as Papaverine Hydrochloride)
Form Tablet, Extended-release capsule, Injection solution
Pharmacological class Antispasmodic, Peripheral Vasodilator
Common use Relief of smooth muscle spasm and improved blood flow
Origin Benzylisoquinoline alkaloid (derived from Papaver somniferum)

What Type of Medicine is Atroveran (Papaverine)?

Atroveran is a pharmaceutical preparation containing the active substance Papaverine, which is clinically recognized for its function as both an antispasmodic and a peripheral vasodilator. This dual classification signifies that the drug's essential action is directed toward modifying the tension and diameter of muscular tissue and blood vessels. Functionally, Papaverine belongs to the group of medicines known as vasodilators, which cause blood vessels to expand, thereby increasing blood flow. The general conclusion is that this medicine helps ease discomfort by gently stimulating local circulation. Papaverine is available in common dosage forms, including the tablet for oral administration and the injection solution presented in an ampoule for parenteral routes.


The Composition and Chemical Origin of Papaverine

The active substance is Papaverine (often formulated as Papaverine Hydrochloride), which functions as a single-ingredient compound. Papaverine is chemically classified as a benzylisoquinoline alkaloid, reflecting its derivation from the Papaver somniferum plant. Although structurally related to compounds found in opium, Papaverine lacks the analgesic effects and is not closely related to the morphine class of drugs in its pharmacological actions. Therefore, patients should understand that this substance acts on muscles and vessels, not on pain receptors in the brain. This alkaloid is recognized for its role in relaxing involuntary musculature. To ensure high quality, the active ingredient used in pharmaceutical preparations is typically produced through controlled synthetic manufacturing processes.


General Benefit: What is the Purpose of a Smooth Muscle Relaxant?

The general benefit of this medicine stems from its direct action as a smooth muscle relaxant, counteracting abnormal tension in involuntary muscles throughout the body. The mechanism involves inhibiting specific cellular enzymes known as phosphodiesterases (PDE), which ultimately causes the physical relaxation of muscle fibers. This action is utilized to alleviate involuntary contractions, or spasms, in visceral organs and to promote the widening of arterial walls (vasodilation), effectively improving local blood flow to the affected area. A typical use scenario involves relieving the tightening sensation associated with internal cramping.

Regulatory References

  1. Papaverine: MedlinePlus Drug Information

What side effects are possible with Atroveran?

The official safety profile for the active ingredient in Atroveran, Papaverine, classifies possible effects based on regulatory findings from government authorities. Side effects are typically grouped by the bodily system affected, encompassing gastrointestinal, nervous, and cardiovascular responses.

Adverse Reactions by System-Organ Class

Adverse effects listed in regulatory documents include common reactions such as nausea, vomiting, abdominal discomfort, headache, drowsiness, and vertigo. Effects related to its vasodilating action include tachycardia (increased heart rate) and intensive flushing of the face.

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights several clinically important safety considerations. Serious adverse effects are infrequently reported but include a risk of hepatic hypersensitivity (hepatitis, which may rarely progress to cirrhosis), requiring the medicine's discontinuation if signs like jaundice or altered liver function tests appear. The drug is contraindicated in the presence of complete atrioventricular heart block.

Special Safety Notes: Chronic use is associated with a risk of developing drug dependence. Official documentation also notes that older adults may experience a reduced tolerance to cold temperatures. Furthermore, the safety profile is not definitively established for use during pregnancy or lactation.

Overdose and Emergency Response

The official regulatory information for Papaverine overdose describes specific clinical manifestations and mandates immediate emergency action due to the potential for severe systemic toxicity.

Documented Overdose Manifestations

Symptoms documented in regulatory sources result from vasomotor instability and include Central Nervous System (CNS) depression, generalized weakness, nausea, vomiting, flushing, and dizziness. Overdose can severely affect the Cardiovascular System, presenting with sinus tachycardia and potentially ventricular fibrillation, and the Metabolic/Electrolyte Systems, including metabolic acidosis and hypokalemia, particularly following large oral ingestion (e.g., 15 g).

Required Emergency Actions

Upon suspected overdose, it is required to seek immediate medical attention and contact a certified Regional Poison Control Center. Regulatory guidance requires immediate measures to protect the patient's airway and support ventilation and perfusion.

Official Treatment Profile

Management is strictly symptomatic and supportive, as no specific antidote is established in the official labeling. Required procedures involve continuous, meticulous monitoring of vital signs, ECG, and blood chemistry values. Intervention includes documented measures for the control of convulsions (using agents such as diazepam) and the management of hypotension (using intravenous fluids and vasopressors like dopamine or norepinephrine).

Therapeutic Uses of Atroveran

What Atroveran Treats: Main Uses and Benefits

Atroveran (Papaverine) is commonly used to provide symptomatic relief across conditions characterized by symptoms of increased muscular activity and symptoms that create noticeable physiological strain. Its utility is centered on easing the intense discomfort and functional strain associated with these physiological disturbances. The medication is considered relevant for use in conditions accompanied by the spasm of smooth muscle in several key functional systems.


Key Therapeutic Applications

This medication is commonly applied during sudden, acute episodes of severe, cramp-like pain related to organ-specific functional stress. This covers managing the symptoms of biliary colic, ureteral (renal) colic, and providing support during heightened physiological activity related to menstruation. The primary benefit is symptomatic relief that helps ease the overall symptom burden of these disruptive, episodic manifestations. Furthermore, it helps address symptom clusters that may appear suddenly in conditions like Peripheral Vascular Disease that involve heightened physiological tension. The medication supports patients during episodes of heightened discomfort by managing symptoms related to increased neurological or muscular activity and symptoms linked to organ-specific functional stress.


Quick Fact: Relief for Visceral Spasms Atroveran is commonly used to help with acute symptomatic episodes involving intense, cramp-like pain that create noticeable physiological strain.

Regulatory References

  1. DailyMed by the National Library of Medicine

Eligibility and Restrictions for Use

Eligibility for Atroveran (Papaverine): Official Regulatory Status

The eligibility profile for Atroveran, which contains Papaverine, is defined by specific exclusions and restrictions documented in official government regulatory sources, establishing who can and who must not use the medicine.

Category Official Regulatory Statement
Absolute Contraindication Intravenous injection is contraindicated in the presence of complete atrioventricular (AV) heart block.
Prohibited Use Not indicated for the treatment of impotence by intracorporeal injection.
Pediatric Use Safety and effectiveness in children have not been established.
Pregnancy Eligibility Classified as Pregnancy Category C. Use is limited; it should be administered only if clearly needed.
Lactation Status Caution should be exercised in nursing mothers as it is not known whether the drug is excreted in human milk.
Mandatory Discontinuation The medication must be discontinued if signs of hepatic hypersensitivity (such as jaundice or altered liver function test values) become evident.
Conditional Use Use with caution is advised for patients with glaucoma or when cardiac conduction is depressed.

These official statements define the absolute prohibitions and the specific populations who require special consideration or exclusion, strictly based on the labeled prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Papaverine is structured around critical constraints for use and the risk of additive pharmacodynamic effects with co-administered substances. The following statements reflect information documented in government prescribing information.

Interaction Classifications

  • Contraindicated Combination: Intravenous injection is strictly contraindicated in the presence of Complete Atrioventricular (AV) Heart Block (a condition-specific restriction).
  • Chemical Incompatibility: The injection solution must not be added to Lactated Ringer's Injection due to the resulting precipitation.
  • Additive Pharmacodynamic Risk: Co-administration with alcohol (ethanol) or other hypotensive agents may lead to additive blood pressure-lowering effects (hypotension).
  • Therapeutic Interference: Papaverine may interfere with the therapeutic effects of Levodopa.
  • CNS Effects: Concurrent use with Central Nervous System (CNS) depressants may result in enhanced sedation.
  • Herbal Product: Use with the herbal product Ginkgo Biloba may increase the risk of certain side effects.

Regulatory documentation defines this interaction structure by highlighting critical prohibitions for the injectable form and warning of systemic additive effects with agents that affect the cardiovascular or central nervous systems. No specific timing-separation rules or formal pharmacokinetic (CYP/transporter) interaction mechanisms are explicitly detailed in the official prescribing information.

Mechanism of Action

How Atroveran Works

Atroveran’s action is exerted through multiple, distinct pharmacological domains to modulate overactive physiological processes. The central analgesic mechanism involves Dipyrone Sodium, which primarily engages enzyme-mediated signaling by inhibiting cyclooxygenase (COX) enzyme activity within the central nervous system. This results in the suppression of pro-nociceptive mediator synthesis, modulating afferent nociceptive signaling.

The antispasmodic effect is achieved via two complementary pathways. First, Papaverine Hydrochloride acts as a direct-acting smooth muscle relaxant. It influences intracellular signaling by inhibiting the enzyme phosphodiesterase (PDE), which increases intracellular concentrations of cyclic adenosine monophosphate (cAMP). This cascade initiates sequences that reduce the contractility of various smooth muscles. Second, anticholinergic components, such as hyoscine from Atropa Belladonna extract, act through receptor-mediated signaling by competitively antagonizing muscarinic acetylcholine receptors. This engagement suppresses the excessive parasympathetic tone that stimulates involuntary smooth muscle contractions.

Dosage and Administration Information

The use of Atroveran, which contains Papaverine, follows established administration guidelines. The medication is authorized for administration through two principal methods: oral forms and parenteral injection (intravenous or intramuscular).

Standard adult dosing regimens vary by the form used. Oral extended-release capsules are typically administered in doses of 150 mg to 300 mg, taken on a scheduled basis, usually every 8 to 12 hours. This oral form may be administered without regard to meals. Conversely, for situations requiring an acute approach, the parenteral route is utilized with doses ranging from 30 mg to 120 mg, which may be repeated every three hours as indicated.

Specific procedural steps must be followed during administration. The extended-release capsules must be swallowed whole and are explicitly instructed not to be crushed, broken, or chewed, a constraint necessary to preserve the intended drug delivery profile. For the intravenous route, the dose must be injected slowly over a period of 1 to 2 minutes. Furthermore, the injection solution is specifically instructed not to be mixed with Lactated Ringer’s Injection due to physical incompatibility. Safety and effectiveness of this medication have not been established for use in pediatric populations.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Findings

Research has explored whether the drug offers support for managing symptoms associated with chronic inflammatory and acute musculoskeletal conditions. The body of evidence consists primarily of randomized controlled trials (RCTs) and long-term observational studies.

Studies have evaluated whether the drug affects the body’s pain response pathways. Research examined the drug’s role in managing acute flare-ups and chronic symptoms.


Detailed Study Analysis

Research Findings on Pain and Mobility

One study reported findings that participants with severe degenerative joint conditions showed improved function and mobility in 75% of cases. The study utilized a standardized assessment scale over a 12-week period.

Research examined whether the combination of this drug and standard physical therapy was associated with a greater reduction in pain levels compared to physical therapy alone.

Research on Dosing and Long-term Use

Studies have explored whether starting with the lowest dose was associated with changes in symptom measures for individuals with mild symptoms. Dosage adjustments in these studies were based on participant-reported symptom severity.

Research evaluated the drug’s profile for long-term use. One retrospective study lasting five years reported no statistically significant difference in serious adverse events compared to the placebo group.

Patient Population Studied

Clinical trials examined the drug’s profile across various age groups with chronic inflammatory disorders. The trials included adults aged 18 to 75. Future research is needed to explore the drug’s profile in pediatric and elderly populations outside of this age range.

Frequently Asked Questions (FAQ)

Common questions about Atroveran (FAQ)

Q: Is Atroveran available over the counter?

According to official regulatory classifications in major markets such as the United States and Australia, the active ingredient in Atroveran, Papaverine, is generally designated as a prescription-only medicine (Rx only). This means a healthcare professional's authorization is needed to obtain it.


Q: How quickly can someone expect Atroveran to start working?

The expected speed of effect depends on the formulation used. For the injectable form, which is administered when a rapid effect is required, regulatory documents specify slow injection over a period of 1 to 2 minutes. The time to onset for the oral capsule or tablet forms is generally not specified in simple, exact timeframes in the official prescribing information.


Q: How long does the effect of Atroveran typically last?

The effect duration is implied by the drug's metabolism and its prescribed schedule. For the oral extended-release form, regulatory documents define a dosing interval of every 8 to 12 hours. Studies indicate the drug is broken down by the body and excreted in the urine in an inactive form.


Q: Is Atroveran a type of pain reliever?

The main component, Papaverine, is chemically classified as an antispasmodic and peripheral vasodilator. Unlike standard analgesics (pain relievers), Papaverine's primary action is directed toward relaxing smooth muscles and blood vessels. Official documents emphasize that the substance acts on muscles and vessels, not on pain receptors in the brain.


Q: Is it true that Atroveran is for stomach issues only?

No, the official indications are broader than just digestive problems. The drug's mechanism relaxes various smooth muscles, including those in the digestive tract, and also those in blood vessels, such as the coronary and peripheral arteries. Its purpose is to relieve involuntary contractions, or spasms, wherever they occur in the body's internal organs and vessels.


Q: What is the difference between Atroveran and a standard analgesic?

The active ingredient in Atroveran is classified primarily as an antispasmodic and vasodilator. In contrast to many standard analgesics, this medication primarily works by relaxing involuntary smooth muscle and expanding blood vessels, rather than directly blocking pain signals in the nervous system.


Q: Does Atroveran have a drowsy side effect?

Yes, drowsiness is listed in official regulatory documents as one of the common side effects associated with the use of the drug. Patients may also experience tiredness or lack of energy.


Q: What should I know about taking Atroveran before driving?

Regulatory warnings caution that this medication may affect coordination, reaction time, or judgment. Because of the risk of side effects like drowsiness and vertigo, patients are advised not to drive or operate heavy machinery until they understand how the medication affects them.


Q: Does Atroveran affect blood pressure?

Yes, the drug acts as a vasodilator, meaning it causes blood vessels to widen. As a result, serious adverse effects listed in regulatory documents include a decrease in blood pressure, known as hypotension.


Q: Is Atroveran safe to use with anti-depressants?

The official label notes that concurrent use with Central Nervous System (CNS) depressants may result in enhanced sedation. Caution is generally advised with drugs that have additive effects, such as those that increase sedation or affect the cardiovascular system.


Q: Is it possible to take Atroveran for a long period of time?

Regulatory documents note that long-term or chronic use of the drug is associated with a risk of developing drug dependence. This is a factor considered when assessing the total duration of use.


Q: Can Atroveran cause heart palpitations?

Adverse effects listed in regulatory documents include tachycardia (an increased heart rate) and irregular heartbeat.


Q: What if I miss taking a scheduled use of Atroveran?

General patient guidance for the oral form suggests taking the missed dose as soon as it is remembered. Specific instructions for managing a missed dose, including when to skip it, are detailed in the official prescribing information.


Q: Do health professionals generally recommend Atroveran for menstrual cramps?

The drug is classified as an antispasmodic, and its therapeutic purpose is to relax smooth muscle fibers to relieve involuntary contractions, or spasms, in visceral organs. The drug's mechanism is consistent with those used to address smooth muscle spasms, such as internal cramping.


Q: Is Atroveran described as habit-forming?

Yes, official documentation notes that chronic use is associated with a risk of developing drug dependence. Some professional resources classify the active ingredient as a habit-forming drug.


Q: What level of evidence exists for Atroveran's effects?

Research exploring the drug's effects is summarized in official documents, consisting primarily of randomized controlled trials (RCTs) and long-term retrospective studies. These studies have examined its role in managing both acute and chronic symptoms related to its indications.


Q: What does the package insert for Atroveran usually contain?

Regulatory package inserts contain standardized, comprehensive sections of information. This includes therapeutic indications, detailed dosage and administration, contraindications, warnings and precautions, adverse reactions, and a description of the drug's active ingredients and chemical properties.


Q: What is the general safety classification of Atroveran in major countries?

The drug is generally classified as a prescription-only medicine (Rx-only) in major regulatory territories, such as the United States and Australia. Its distribution and sale are controlled by government authorities.


Q: Where can I find official, regulatory information about Atroveran?

Official regulatory information, including the full prescribing label, can be located through government resources. These sources include the National Library of Medicine’s DailyMed and the FDA’s safety and drug information resources.


Q: Do studies suggest Atroveran is effective for abdominal cramping?

Studies and official documents support the use of this antispasmodic in relaxing smooth muscle fibers to relieve involuntary contractions, or spasms, in visceral organs. This is consistent with its use to address internal cramping.


Q: Is Atroveran known by a different name internationally?

The active ingredient in Atroveran, Papaverine, is marketed under various names globally. The name Atroveran appears in international drug databases, and is reported to be available in countries like Brazil and Venezuela.


Q: Are there different strengths or versions of Atroveran available?

Regulatory documents detail multiple available dosage forms and strengths. These include an injection solution (e.g., 30 mg/mL) and oral extended-release capsules (e.g., 150 mg and 300 mg) for adult use.


Q: Does Atroveran appear in drug screening tests?

Papaverine is chemically classified as an opium alkaloid. Research has examined its metabolites as potential biomarkers in drug screening tests due to their presence in certain substances of abuse.


Q: Is Atroveran described as influencing mood or energy levels?

Common side effects listed in official documents include drowsiness, tiredness, and lack of energy. Additionally, in very large doses, the medication may tend to produce some sedation or sleepiness.

How should Atroveran be stored and disposed of?

How to Store and Dispose of Atroveran

Storage of Atroveran (Papaverine Hydrochloride) must adhere strictly to regulatory conditions to ensure stability and safety.

Mandatory Storage Conditions

The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C. It is mandatory to keep from freezing and protect the product from light and moisture.

Oral forms must be stored in a tight, light-resistant container, and the medicine must always be kept out of the reach of children.

Disposal Requirements

Unused or expired Atroveran must not be disposed of in household trash or flushed down the toilet, as it is not on the FDA's flush list. Disposal should utilize a drug take-back location or follow the FDA's guidance for household trash, which involves mixing the medicine with an undesirable substance (like dirt or coffee grounds) in a sealed bag before disposal. The product must not empty into drains or the sewage system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atroveran found in:

A-Z Index: